Evidence map›Paper›PMID 35367438›Full record

ArticleAmerican journal of ophthalmology2022

Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation.

Emily Wiecek, James D Akula, Deborah K Vanderveen, Iason S Mantagos, Carolyn Wu, Amber-Lee Curran, Hanna De Bruyn, Bridget Peterson, Anne B Fulton

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Long-term visual function and refractive changes after vitrectomy for stage 4 retinopathy of prematurity.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Emily WiecekFrom Boston Children's Hospital (E.W., J.A., D.V., I.M., C.W., A-L.C., H.D., B.P., A.F.), Boston, Massachusetts, USA; Harvard Medical School (E.W., J.A., D.V., I.M., C.W., A.F.), Boston, Massachusetts, USA. Electronic address: emily.wiecek@childrens.harvard.edu.
James D AkulaFrom Boston Children's Hospital (E.W., J.A., D.V., I.M., C.W., A-L.C., H.D., B.P., A.F.), Boston, Massachusetts, USA; Harvard Medical School (E.W., J.A., D.V., I.M., C.W., A.F.), Boston, Massachusetts, USA.
Deborah K VanderveenFrom Boston Children's Hospital (E.W., J.A., D.V., I.M., C.W., A-L.C., H.D., B.P., A.F.), Boston, Massachusetts, USA; Harvard Medical School (E.W., J.A., D.V., I.M., C.W., A.F.), Boston, Massachusetts, USA.
Iason S MantagosFrom Boston Children's Hospital (E.W., J.A., D.V., I.M., C.W., A-L.C., H.D., B.P., A.F.), Boston, Massachusetts, USA; Harvard Medical School (E.W., J.A., D.V., I.M., C.W., A.F.), Boston, Massachusetts, USA.
Carolyn WuFrom Boston Children's Hospital (E.W., J.A., D.V., I.M., C.W., A-L.C., H.D., B.P., A.F.), Boston, Massachusetts, USA; Harvard Medical School (E.W., J.A., D.V., I.M., C.W., A.F.), Boston, Massachusetts, USA.
Amber-Lee CurranFrom Boston Children's Hospital (E.W., J.A., D.V., I.M., C.W., A-L.C., H.D., B.P., A.F.), Boston, Massachusetts, USA.
Hanna De BruynFrom Boston Children's Hospital (E.W., J.A., D.V., I.M., C.W., A-L.C., H.D., B.P., A.F.), Boston, Massachusetts, USA.
Bridget PetersonFrom Boston Children's Hospital (E.W., J.A., D.V., I.M., C.W., A-L.C., H.D., B.P., A.F.), Boston, Massachusetts, USA.
Anne B FultonFrom Boston Children's Hospital (E.W., J.A., D.V., I.M., C.W., A-L.C., H.D., B.P., A.F.), Boston, Massachusetts, USA; Harvard Medical School (E.W., J.A., D.V., I.M., C.W., A.F.), Boston, Massachusetts, USA.
Boston Children's Hospital · US

Funding

Photoreceptor Function in ROPR01EY010597 · NEI · CHILDREN'S HOSPITAL BOSTON · PI FULTON, ANNE B · 1994 to 2023
$10.7M
Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI SCOTT Loren POMEROY, MUSTAFA SAHIN · 2021 to 2026
$9.4M
Noninvasive Protection Against Retinopathy of PrematurityR01EY028953 · NEI · BOSTON CHILDREN'S HOSPITAL · PI AKULA, JAMES DANIEL · 2019 to 2021
$1.3M
NEI NIH HHS R01 EY010597NEI NIH HHS R01 EY028953NICHD NIH HHS P50 HD105351
6 · The paper itself

Abstract

purposeTo compare progression of myopia and refractive error in former premature infants with retinopathy of prematurity (ROP) treated using intravitreal bevacizumab (IVB) or laser.

designRetrospective clinical cohort study.

methodsWe identified premature infants with ROP treated using IVB from 2011 to 2020 and compared their longitudinal cycloplegic refraction data to that of infants with ROP treated using laser during the same timeframe. A subset of infants treated using IVB also underwent additional treatment using laser. We included cycloplegic refractions from 789 cumulative visits over a median 3.2 years. We used a linear mixed-effects model with a log decay function to evaluate how refraction changed with age after treatment.

resultsIn aggregate, the model estimated a significant (P < .001) trend in refraction-from slight hyperopia to relatively more myopic states. However, progression in laser-treated eyes was significantly (P < .001) more rapid, regardless of treatment with IVB. The number of laser spots resulted in increased myopic progression by approximately 0.16 diopters per 100 laser spots. Both ROP stage and zone had a significant effect on myopic progression, with more severe disease resulting in faster myopic progression. Random effects, including individual subject variation with nested variance for left and right eye, accounted for 86.4% of the remaining variance not explained by age and treatment.

conclusionsLaser treatment for severe ROP increases the trend to severe myopia. In our sample, IVB did not affect myopic progression but did substantially reduce the amount of consequent laser required to treat ROP. The effect of laser persists after accounting for differences in ROP stage and zone.

Indexed as

MyopiaRefractive ErrorsRetinopathy of PrematurityAngiogenesis InhibitorsBevacizumabCohort StudiesGestational AgeHumansInfantInfant, NewbornIntravitreal InjectionsLaser CoagulationMydriaticsRetrospective StudiesAngiogenesis InhibitorsBevacizumabMydriatics

Identifiers

PMID35367438
PMCPMC9308642
OpenAlexW4220821050

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.